Sol-Gel Technologies develops and commercializes topical dermatological medications, primarily using its proprietary silica-based delivery technologies. It markets the FDA-approved products TWYNEO for the treatment of acne vulgaris and EPSOLAY for papulopustular rosacea, while advancing clinical candidates such as SGT-610 for Gorlin syndrome and other rare skin disorders. The company operates from Israel and partners with global pharmaceutical firms to reach patients in multiple countries.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 17.3 | — | 11.6 | — |
| Q3 2025 | 0.4 | — | -5.9 | — |
| Q4 2025 | 0.7 | — | -3 | — |
| Q1 2026 | 0.1 | — | -3.7 | — |
| Q2 2026 | 0.6 | -96.6% | -3.7 | -131.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Capital, Inc. (FCAP), The Lovesac Company (LOVE), Translational Development Acquisition Corp. (TDAC), Zentalis Pharmaceuticals, Inc. (ZNTL), Chicago Atlantic BDC, Inc. (LIEN), ZenaTech, Inc. (ZENA)